BillionToOne received $130 million investment with a valuation of over $1 billion

Health initiative, of which Oğuzhan Atay is one of the founders BillionToOneWe have previously informed you that ‘s investment amounted to 125 million dollars in the C series investment round. we had transferred. The company came to the fore with news of a new investment.

BillionToOne, $130 million announced that it received an investment. Valuation of the company $1 billion He climbed on it. The company’s D series investment round Premji Invest Managed by. Neuberger Berman, Adam Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital and Fifty Years took part in the investment round of the US-based company. The company announced that it will use the investment to develop new products and increase marketing activities.

BillionToOne in 2016 David Tsao, Oguzhan Atay ve Sukrit Silas was founded by The company develops special technologies aimed at precise diagnosis of diseases in the healthcare sector. These technologies, which are used especially in prenatal screening and oncology diagnoses, have the ability to count DNA molecules with single base pair precision. In this way, they help improve the management of treatment processes by providing more accurate and reliable diagnoses to patients.

Prenatal tests such as UNITY Fetal Risk Screen from BillionToOne are used to evaluate genetic risks during pregnancy, while Northstar Select® and Northstar Response® are used in oncology to determine treatment options and monitor response to treatment. These products have lower detection limits and aim to provide more sensitive and personalized treatment approaches for patients.

BillionToOne’s main goal is to raise standards in healthcare by making prenatal screening and oncology diagnoses more accurate, sensitive and accessible by developing technologies used in molecular diagnostics.